In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018–2020
This study aimed to investigate the in vitro susceptibilities of carbapenem-non-susceptible Pseudomonas aeruginosa (CNSPA) and Acinetobacter baumannii (CNSAB) isolates to cefiderocol, novel β-lactamase inhibitor (BLI) combinations, new tetracycline analogues, and other comparative antibiotics. In to...
Saved in:
| Published in | Journal of microbiology, immunology and infection Vol. 55; no. 5; pp. 888 - 895 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier B.V
01.10.2022
Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | This study aimed to investigate the in vitro susceptibilities of carbapenem-non-susceptible Pseudomonas aeruginosa (CNSPA) and Acinetobacter baumannii (CNSAB) isolates to cefiderocol, novel β-lactamase inhibitor (BLI) combinations, new tetracycline analogues, and other comparative antibiotics.
In total, 405 non-duplicate bacteremic CNSPA (n = 150) and CNSAB (n = 255) isolates were collected from 16 hospitals in Taiwan between 2018 and 2020. Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method, and susceptibilities were interpreted according to the relevant guidelines or in accordance with results of previous studies and non-species-related pharmacokinetic/pharmacodynamic data.
Among the isolates tested, cefiderocol demonstrated potent in vitro activity against CNSPA (MIC50/90, 0.25/1 mg/L; 100% of isolates were inhibited at ≤4 mg/L) and CNSAB (MIC50/90, 0.5/2 mg/L; 94.9% of isolates were inhibited at ≤4 mg/L) isolates. More than 80% of CNSPA isolates were susceptible to cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, and amikacin, based on breakpoints established by the Clinical and Laboratory Standards Institute. Activities of new BLI combinations varied significantly. Tetracycline analogues, including tigecycline (MIC50/90, 1/2 mg/L; 92.5% of CNSAB isolates were inhibited at ≤2 mg/L) and eravacycline (MIC50/90, 0.5/1 mg/L; 99.6% of CNSAB isolates were inhibited at ≤2 mg/L) exhibited more potent in vitro activity against CNSAB than omadacycline (MIC50/90, 4/8 mg/L).
The spread of CNSPA and CNSAB poses a major challenge to global health. Significant resistance be developed even before a novel agent becomes commercially available. The development of on-site antimicrobial susceptibility tests for these novel agents is of great clinical importance. |
|---|---|
| AbstractList | This study aimed to investigate the in vitro susceptibilities of carbapenem-non-susceptible Pseudomonas aeruginosa (CNSPA) and Acinetobacter baumannii (CNSAB) isolates to cefiderocol, novel β-lactamase inhibitor (BLI) combinations, new tetracycline analogues, and other comparative antibiotics.BACKGROUND/PURPOSEThis study aimed to investigate the in vitro susceptibilities of carbapenem-non-susceptible Pseudomonas aeruginosa (CNSPA) and Acinetobacter baumannii (CNSAB) isolates to cefiderocol, novel β-lactamase inhibitor (BLI) combinations, new tetracycline analogues, and other comparative antibiotics.In total, 405 non-duplicate bacteremic CNSPA (n = 150) and CNSAB (n = 255) isolates were collected from 16 hospitals in Taiwan between 2018 and 2020. Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method, and susceptibilities were interpreted according to the relevant guidelines or in accordance with results of previous studies and non-species-related pharmacokinetic/pharmacodynamic data.METHODSIn total, 405 non-duplicate bacteremic CNSPA (n = 150) and CNSAB (n = 255) isolates were collected from 16 hospitals in Taiwan between 2018 and 2020. Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method, and susceptibilities were interpreted according to the relevant guidelines or in accordance with results of previous studies and non-species-related pharmacokinetic/pharmacodynamic data.Among the isolates tested, cefiderocol demonstrated potent in vitro activity against CNSPA (MIC50/90, 0.25/1 mg/L; 100% of isolates were inhibited at ≤4 mg/L) and CNSAB (MIC50/90, 0.5/2 mg/L; 94.9% of isolates were inhibited at ≤4 mg/L) isolates. More than 80% of CNSPA isolates were susceptible to cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, and amikacin, based on breakpoints established by the Clinical and Laboratory Standards Institute. Activities of new BLI combinations varied significantly. Tetracycline analogues, including tigecycline (MIC50/90, 1/2 mg/L; 92.5% of CNSAB isolates were inhibited at ≤2 mg/L) and eravacycline (MIC50/90, 0.5/1 mg/L; 99.6% of CNSAB isolates were inhibited at ≤2 mg/L) exhibited more potent in vitro activity against CNSAB than omadacycline (MIC50/90, 4/8 mg/L).RESULTSAmong the isolates tested, cefiderocol demonstrated potent in vitro activity against CNSPA (MIC50/90, 0.25/1 mg/L; 100% of isolates were inhibited at ≤4 mg/L) and CNSAB (MIC50/90, 0.5/2 mg/L; 94.9% of isolates were inhibited at ≤4 mg/L) isolates. More than 80% of CNSPA isolates were susceptible to cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, and amikacin, based on breakpoints established by the Clinical and Laboratory Standards Institute. Activities of new BLI combinations varied significantly. Tetracycline analogues, including tigecycline (MIC50/90, 1/2 mg/L; 92.5% of CNSAB isolates were inhibited at ≤2 mg/L) and eravacycline (MIC50/90, 0.5/1 mg/L; 99.6% of CNSAB isolates were inhibited at ≤2 mg/L) exhibited more potent in vitro activity against CNSAB than omadacycline (MIC50/90, 4/8 mg/L).The spread of CNSPA and CNSAB poses a major challenge to global health. Significant resistance be developed even before a novel agent becomes commercially available. The development of on-site antimicrobial susceptibility tests for these novel agents is of great clinical importance.CONCLUSIONSThe spread of CNSPA and CNSAB poses a major challenge to global health. Significant resistance be developed even before a novel agent becomes commercially available. The development of on-site antimicrobial susceptibility tests for these novel agents is of great clinical importance. This study aimed to investigate the in vitro susceptibilities of carbapenem-non-susceptible Pseudomonas aeruginosa (CNSPA) and Acinetobacter baumannii (CNSAB) isolates to cefiderocol, novel β-lactamase inhibitor (BLI) combinations, new tetracycline analogues, and other comparative antibiotics. In total, 405 non-duplicate bacteremic CNSPA (n = 150) and CNSAB (n = 255) isolates were collected from 16 hospitals in Taiwan between 2018 and 2020. Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method, and susceptibilities were interpreted according to the relevant guidelines or in accordance with results of previous studies and non-species-related pharmacokinetic/pharmacodynamic data. Among the isolates tested, cefiderocol demonstrated potent in vitro activity against CNSPA (MIC50/90, 0.25/1 mg/L; 100% of isolates were inhibited at ≤4 mg/L) and CNSAB (MIC50/90, 0.5/2 mg/L; 94.9% of isolates were inhibited at ≤4 mg/L) isolates. More than 80% of CNSPA isolates were susceptible to cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, and amikacin, based on breakpoints established by the Clinical and Laboratory Standards Institute. Activities of new BLI combinations varied significantly. Tetracycline analogues, including tigecycline (MIC50/90, 1/2 mg/L; 92.5% of CNSAB isolates were inhibited at ≤2 mg/L) and eravacycline (MIC50/90, 0.5/1 mg/L; 99.6% of CNSAB isolates were inhibited at ≤2 mg/L) exhibited more potent in vitro activity against CNSAB than omadacycline (MIC50/90, 4/8 mg/L). The spread of CNSPA and CNSAB poses a major challenge to global health. Significant resistance be developed even before a novel agent becomes commercially available. The development of on-site antimicrobial susceptibility tests for these novel agents is of great clinical importance. Background/purpose: This study aimed to investigate the in vitro susceptibilities of carbapenem-non-susceptible Pseudomonas aeruginosa (CNSPA) and Acinetobacter baumannii (CNSAB) isolates to cefiderocol, novel β-lactamase inhibitor (BLI) combinations, new tetracycline analogues, and other comparative antibiotics. Methods: In total, 405 non-duplicate bacteremic CNSPA (n = 150) and CNSAB (n = 255) isolates were collected from 16 hospitals in Taiwan between 2018 and 2020. Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method, and susceptibilities were interpreted according to the relevant guidelines or in accordance with results of previous studies and non-species-related pharmacokinetic/pharmacodynamic data. Results: Among the isolates tested, cefiderocol demonstrated potent in vitro activity against CNSPA (MIC50/90, 0.25/1 mg/L; 100% of isolates were inhibited at ≤4 mg/L) and CNSAB (MIC50/90, 0.5/2 mg/L; 94.9% of isolates were inhibited at ≤4 mg/L) isolates. More than 80% of CNSPA isolates were susceptible to cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, and amikacin, based on breakpoints established by the Clinical and Laboratory Standards Institute. Activities of new BLI combinations varied significantly. Tetracycline analogues, including tigecycline (MIC50/90, 1/2 mg/L; 92.5% of CNSAB isolates were inhibited at ≤2 mg/L) and eravacycline (MIC50/90, 0.5/1 mg/L; 99.6% of CNSAB isolates were inhibited at ≤2 mg/L) exhibited more potent in vitro activity against CNSAB than omadacycline (MIC50/90, 4/8 mg/L). Conclusions: The spread of CNSPA and CNSAB poses a major challenge to global health. Significant resistance be developed even before a novel agent becomes commercially available. The development of on-site antimicrobial susceptibility tests for these novel agents is of great clinical importance. This study aimed to investigate the in vitro susceptibilities of carbapenem-non-susceptible Pseudomonas aeruginosa (CNSPA) and Acinetobacter baumannii (CNSAB) isolates to cefiderocol, novel β-lactamase inhibitor (BLI) combinations, new tetracycline analogues, and other comparative antibiotics. In total, 405 non-duplicate bacteremic CNSPA (n = 150) and CNSAB (n = 255) isolates were collected from 16 hospitals in Taiwan between 2018 and 2020. Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method, and susceptibilities were interpreted according to the relevant guidelines or in accordance with results of previous studies and non-species-related pharmacokinetic/pharmacodynamic data. Among the isolates tested, cefiderocol demonstrated potent in vitro activity against CNSPA (MIC , 0.25/1 mg/L; 100% of isolates were inhibited at ≤4 mg/L) and CNSAB (MIC , 0.5/2 mg/L; 94.9% of isolates were inhibited at ≤4 mg/L) isolates. More than 80% of CNSPA isolates were susceptible to cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, and amikacin, based on breakpoints established by the Clinical and Laboratory Standards Institute. Activities of new BLI combinations varied significantly. Tetracycline analogues, including tigecycline (MIC , 1/2 mg/L; 92.5% of CNSAB isolates were inhibited at ≤2 mg/L) and eravacycline (MIC , 0.5/1 mg/L; 99.6% of CNSAB isolates were inhibited at ≤2 mg/L) exhibited more potent in vitro activity against CNSAB than omadacycline (MIC , 4/8 mg/L). The spread of CNSPA and CNSAB poses a major challenge to global health. Significant resistance be developed even before a novel agent becomes commercially available. The development of on-site antimicrobial susceptibility tests for these novel agents is of great clinical importance. |
| Author | Lu, Po-Liang Shi, Zhi-Yuan Liu, Chang-Pan Lu, Min-Chi Wang, Lih-Shinn Lin, Chao-Nan Chen, Yu-Hui Lee, Chun-Ming Tseng, Shu-Hui Wu, Ting-Shu Hsueh, Po-Ren Lin, Chi-Ying Sheng, Wang-Huei Liu, Po-Yu Cheng, Shu-Hsing Chen, Yen-Hsu Tang, Hung-Jen Yen, Muh-Yong Wang, Fu-Der Chen, Yao-Shen Lee, Wen-Sen Shao, Pei-Lan Ko, Wen-Chien Lee, Yu-Lin |
| Author_xml | – sequence: 1 givenname: Po-Yu surname: Liu fullname: Liu, Po-Yu organization: Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan – sequence: 2 givenname: Wen-Chien surname: Ko fullname: Ko, Wen-Chien organization: Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan – sequence: 3 givenname: Wen-Sen surname: Lee fullname: Lee, Wen-Sen organization: Division of Infectious Diseases, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan – sequence: 4 givenname: Po-Liang surname: Lu fullname: Lu, Po-Liang organization: Department of Internal Medicine, Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan – sequence: 5 givenname: Yen-Hsu surname: Chen fullname: Chen, Yen-Hsu organization: Department of Internal Medicine, Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan – sequence: 6 givenname: Shu-Hsing surname: Cheng fullname: Cheng, Shu-Hsing organization: Department of Internal Medicine, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan – sequence: 7 givenname: Min-Chi surname: Lu fullname: Lu, Min-Chi organization: Department of Microbiology and Immunology, School of Medicine, China Medical University, Taichung, Taiwan – sequence: 8 givenname: Chi-Ying surname: Lin fullname: Lin, Chi-Ying organization: Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan – sequence: 9 givenname: Ting-Shu surname: Wu fullname: Wu, Ting-Shu organization: Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan – sequence: 10 givenname: Muh-Yong surname: Yen fullname: Yen, Muh-Yong organization: Division of Infectious Diseases, Taipei City Hospital, National Yang-Ming University, School of Medicine, Taipei, Taiwan – sequence: 11 givenname: Lih-Shinn surname: Wang fullname: Wang, Lih-Shinn organization: Division of Infectious Diseases, Department of Internal Medicine, Buddhist Tzu Chi General Hospital, Hualien, Taiwan – sequence: 12 givenname: Chang-Pan surname: Liu fullname: Liu, Chang-Pan organization: Division of Infectious Diseases, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan – sequence: 13 givenname: Pei-Lan surname: Shao fullname: Shao, Pei-Lan organization: Department of Pediatrics, Hsin-Chu Branch, National Taiwan University Hospital, Hsin-Chu, Taiwan – sequence: 14 givenname: Yu-Lin surname: Lee fullname: Lee, Yu-Lin organization: Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan – sequence: 15 givenname: Zhi-Yuan surname: Shi fullname: Shi, Zhi-Yuan organization: Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan – sequence: 16 givenname: Yao-Shen surname: Chen fullname: Chen, Yao-Shen organization: Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan – sequence: 17 givenname: Fu-Der surname: Wang fullname: Wang, Fu-Der organization: School of Medicine, National Yang-Ming University, Taipei, Taiwan – sequence: 18 givenname: Shu-Hui surname: Tseng fullname: Tseng, Shu-Hui organization: Center for Disease Control and Prevention, Ministry of Health and Welfare, Taiwan – sequence: 19 givenname: Chao-Nan surname: Lin fullname: Lin, Chao-Nan organization: Department of Veterinary Medicine, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung, Taiwan – sequence: 20 givenname: Yu-Hui surname: Chen fullname: Chen, Yu-Hui organization: Infection Control Center, Chi Mei Hospital, Liouying, Taiwan – sequence: 21 givenname: Wang-Huei surname: Sheng fullname: Sheng, Wang-Huei organization: Division of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan – sequence: 22 givenname: Chun-Ming surname: Lee fullname: Lee, Chun-Ming organization: Department of Internal Medicine, St Joseph's Hospital, Yunlin County, Taiwan – sequence: 23 givenname: Hung-Jen surname: Tang fullname: Tang, Hung-Jen organization: Department of Medicine, Chi Mei Medical Center, Tainan, Taiwan – sequence: 24 givenname: Po-Ren surname: Hsueh fullname: Hsueh, Po-Ren email: hsporen@gamil.com organization: Division of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34521591$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUktuFDEUbFAQ-cAFWCAvWaQntvsz3YhNFPGJFAkWYd16tp-Dh7Y92O6JJivuwAU4C0fhJHgySUBZhJWfn6vq2eXaL3acd1gULxidMcrao8VsYY2ZccrZjHYzyvjjYo_1fVP2rKp2ct12dclYx3eL_RgXlNYVb9qnxW5VN5w1Pdt7dHjqfv1cmRQ8AZlMrtbEayJRG4XBSz8ebja4NBaP0FlMcOVFhoL95-Aqg2-bGGAFci1H4_CQeAvq7w6cIj59wUCkt0sIkCcigQt0KeYFjIuJSAgClujQlvnBZZyixGUyYkTyKeKkvPUOMhzDdGGcj3AteyzzhHR9tSwvYLLgnDHERD9CwoyP0UuTS0V08JaI0XsVU0CwxDiN-fXe5Yqcg7kERwSmS0RHOGXd7-8_ssv0WfFEwxjx-c16UHx-9_b85EN59vH96cnxWSkbNk9lC43GZj5vay3bvqNCqLapKRfIa9GhptB0uhUdl3PsWll3msu-rbDSolc1V9VBcbrVVR4WwzIYC2E9eDDDdcOHiwFCMnLEQVW1qirN8yfXNVUUdEOFRqqaPJXVOmu92motg_82YUyDNdnQcQSHfooDb-a853U3pxn68gY6CYvqbvBtWjKAbwEy-BgD6jsIo8MmksNi2ERy2ERyoN2QI5lJ3T2SNAk2ZqcAZnyY-mZLxWz2ymAYojToJCoT8n9lN8zD9Nf36JsYGgnjV1z_j_wHPcoZ5A |
| CitedBy_id | crossref_primary_10_3390_ph15040463 crossref_primary_10_3390_antibiotics13121152 crossref_primary_10_1016_j_ijantimicag_2023_106930 crossref_primary_10_1128_AAC_02000_21 crossref_primary_10_1093_jac_dkae426 crossref_primary_10_3389_fphar_2022_896971 crossref_primary_10_1016_j_jmii_2023_07_012 crossref_primary_10_1016_j_heliyon_2024_e33114 crossref_primary_10_1186_s12941_024_00759_3 crossref_primary_10_3389_fmicb_2024_1417237 crossref_primary_10_1080_14787210_2024_2412637 crossref_primary_10_1016_j_ijantimicag_2022_106707 crossref_primary_10_1128_spectrum_00542_22 crossref_primary_10_3390_ijms25136814 crossref_primary_10_1080_14787210_2024_2351552 crossref_primary_10_1016_j_ijantimicag_2023_106867 crossref_primary_10_1016_j_biopha_2024_117666 crossref_primary_10_3389_fcimb_2024_1356353 crossref_primary_10_1016_j_ijantimicag_2023_106882 crossref_primary_10_1016_j_ijid_2022_12_010 crossref_primary_10_3390_biomedicines12112532 crossref_primary_10_1128_aac_01087_24 crossref_primary_10_1016_j_meegid_2023_105420 crossref_primary_10_3389_fcimb_2022_823684 crossref_primary_10_1097_QCO_0000000000000974 crossref_primary_10_1080_17425255_2024_2427310 |
| Cites_doi | 10.1128/AAC.00514-19 10.1016/j.jmii.2014.10.006 10.1016/j.jmii.2019.04.008 10.1093/cid/ciw201 10.1016/j.jmii.2018.05.007 10.3390/jcm9010275 10.3201/eid2507.181200 10.2147/IDR.S193638 10.1093/ofid/ofaa083 10.1186/s13756-017-0208-x 10.1093/jac/dkab008 10.1016/j.jmii.2019.08.017 10.1016/j.jmii.2019.03.004 10.1093/jac/dkf807 10.1093/cid/ciz394 10.1016/j.jmii.2020.04.009 10.1186/s12866-016-0719-2 10.1126/science.aau4679 10.1093/jac/dkx136 10.1128/AAC.01726-20 10.1016/j.jmii.2019.08.007 10.1128/JCM.00635-16 10.1128/AAC.00018-17 10.1093/jac/dky425 10.1016/j.jmii.2019.09.007 10.1038/srep11715 10.1093/jac/dkab015 10.1371/journal.pone.0205166 10.1093/jac/dkaa478 10.3389/fmicb.2019.00080 10.1016/j.ajic.2019.03.003 10.1016/S1473-3099(17)30753-3 10.1093/ofid/ofx163.896 10.1016/j.jmii.2019.06.008 10.1093/jac/dky019 10.1016/j.coph.2011.07.005 10.1080/14787210.2019.1612240 10.1128/CMR.00066-16 10.1016/j.jmii.2018.03.001 |
| ContentType | Journal Article |
| Copyright | 2021 Copyright © 2021. Published by Elsevier B.V. |
| Copyright_xml | – notice: 2021 – notice: Copyright © 2021. Published by Elsevier B.V. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA |
| DOI | 10.1016/j.jmii.2021.08.012 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1995-9133 |
| EndPage | 895 |
| ExternalDocumentID | oai_doaj_org_article_d34d33f2182440d0af50bfe0d5bbd14f 34521591 10_1016_j_jmii_2021_08_012 S1684118221001869 |
| Genre | Journal Article |
| GeographicLocations | Taiwan |
| GeographicLocations_xml | – name: Taiwan |
| GroupedDBID | --- --K .1- .FO .~1 0R~ 1B1 1P~ 1~. 1~5 2WC 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ AAEDW AAIKJ AALRI AAQFI AARKO AAXUO AAYWO ABBQC ABFRF ABMAC ABWVN ABXDB ACGFS ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO ADVLN AEFWE AEKER AENEX AEUPX AEVXI AEXQZ AFJKZ AFPUW AFRHN AFTJW AGEKW AGHFR AGYEJ AIGII AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP BAWUL BCNDV DIK DU5 E3Z EBS EJD EP3 F5P FDB FEDTE FIRID FNPLU GBLVA GROUPED_DOAJ HVGLF HZ~ J1W LUGTX M41 MO0 N9A O-L O9- OD- OK1 OO. P-8 P-9 PC. Q38 ROL SDF SEL SES SSZ UNMZH WH7 Z5R 0SF 6I. AACTN AAFTH LCYCR NCXOZ RIG AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c517t-6a5fe57764fc6980bbd65402be24b8ef0a58f6b82c7e86c48f2c963e3fb9d42d3 |
| IEDL.DBID | .~1 |
| ISSN | 1684-1182 1995-9133 |
| IngestDate | Wed Aug 27 01:31:40 EDT 2025 Fri Jul 11 11:34:54 EDT 2025 Mon Jul 21 06:02:26 EDT 2025 Thu Apr 24 23:00:50 EDT 2025 Tue Jul 01 04:09:38 EDT 2025 Fri Feb 23 02:39:53 EST 2024 Tue Aug 26 16:33:59 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Eravacycline Cefepime/zidebactam Cefepime/enmetazobactam Cefiderocol Omadacycline |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2021. Published by Elsevier B.V. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c517t-6a5fe57764fc6980bbd65402be24b8ef0a58f6b82c7e86c48f2c963e3fb9d42d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S1684118221001869 |
| PMID | 34521591 |
| PQID | 2572924870 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d34d33f2182440d0af50bfe0d5bbd14f proquest_miscellaneous_2572924870 pubmed_primary_34521591 crossref_primary_10_1016_j_jmii_2021_08_012 crossref_citationtrail_10_1016_j_jmii_2021_08_012 elsevier_sciencedirect_doi_10_1016_j_jmii_2021_08_012 elsevier_clinicalkey_doi_10_1016_j_jmii_2021_08_012 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | October 2022 2022-10-00 2022-Oct 20221001 2022-10-01 |
| PublicationDateYYYYMMDD | 2022-10-01 |
| PublicationDate_xml | – month: 10 year: 2022 text: October 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Journal of microbiology, immunology and infection |
| PublicationTitleAlternate | J Microbiol Immunol Infect |
| PublicationYear | 2022 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Jean, Chang, Lin, Lee, Hsueh, Hsu (bib4) 2020; 9 Liu, Li, Li, Du, He, Tao (bib6) 2015; 5 (bib19) 2021 Suzuki, Perencevich, Goto, Alexander, Nair, Puig-Asensio (bib1) 2021; 76 Bartsch, Huang, Wong, Slayton, McKinnell, Sahm (bib38) 2016; 54 Lin, Chiang, Lee, Chang, Fang (bib40) 2020; 53 Morrissey, Magnet, Hawser, Shapiro, Knechtle (bib20) 2019; 63 Gallagher (bib35) 2019; 69 Su, Lee, Liu, Chuang, Chen, Lee (bib37) 2019; 52 Baltas, Stockdale, Tausan, Kashif, Anwar, Anvar (bib11) 2021; 76 Roope, Smith, Pouwels, Buchanan, Abel, Eibich (bib24) 2019; 364 Humphries, Hindler (bib16) 2016; 63 Liu, Shih, Chuang, Wang, Sheng (bib2) 2019; 52 Livermore, Mushtaq, Meunier, Hopkins, Hill, Adkin (bib29) 2017; 72 Morency-Potvin, Schwartz, Weinstein (bib36) 2017; 30 Zheng, Huang, Huang, Ye (bib23) 2020; 53 Jean, Hsueh, Lee, Hsueh (bib28) 2019; 17 Jackson, Czaplewski, Piddock (bib12) 2018; 73 Kao, Chen, Hung, Wu, Hsueh, Yan (bib30) 2016; 16 Walters, Grass, Bulens, Hancock, Phipps, Muleta (bib8) 2019; 25 Pfaller, Huband, Rhomberg, Flamm (bib33) 2017; 61 Felmingham (bib18) 2002; 50 Liu, Chiang, Liu, Kuo, Yang, Lee (bib21) 2019; 52 Morrissey, Magnet, Hawser, Shapiro, Seifert, Higgins (bib32) 2017; 4 Bhavnani, Krause, Ambrose (bib26) 2020; 7 Sheu, Chang, Lin, Chen, Hsueh (bib3) 2019; 10 Feng, Huang, Wang, Yuan, Li, Xia (bib5) 2021; 52 Koizumi, Sakanashi, Ohno, Yamada, Shiota, Kato (bib41) 2019; 52 Kallberg, Ardal, Salvesen Blix, Klein, Elena, Lindbaek (bib15) 2018; 13 Martinez, Baquero, Andersson (bib25) 2011; 11 Du, Xu, Yao, Deng, Chen, Shen (bib9) 2019; 47 Elabbadi, Pont, Verdet, Plesiat, Cretin, Voiriot (bib22) 2020; 53 Morrissey, Olesky, Hawser, Lob, Karlowsky, Corey (bib34) 2020; 64 Yang, Guo, Yin, Zheng, Wu, Zhu (bib31) 2020; 65 Parsels, Mastro, Steele, Thomas, Kufel (bib27) 2021; 76 Chusri, Chongsuvivatwong, Silpapojakul, Singkhamanan, Hortiwakul, Charernmak (bib7) 2019; 52 Liu, Shih, Wang, Wu, Sun, Chow (bib10) 2016; 49 Liao, Lee, Tang, Lee, Lin, Lu (bib14) 2019; 12 Hsueh, Lee, Huang, Liao, Tsuji, Hsueh (bib13) 2019; 74 Tacconelli, Carrara, Savoldi, Harbarth, Mendelson, Monnet (bib17) 2018; 18 Ayukekbong, Ntemgwa, Atabe (bib39) 2017; 6 (10.1016/j.jmii.2021.08.012_bib19) 2021 Morency-Potvin (10.1016/j.jmii.2021.08.012_bib36) 2017; 30 Elabbadi (10.1016/j.jmii.2021.08.012_bib22) 2020; 53 Morrissey (10.1016/j.jmii.2021.08.012_bib32) 2017; 4 Pfaller (10.1016/j.jmii.2021.08.012_bib33) 2017; 61 Jean (10.1016/j.jmii.2021.08.012_bib4) 2020; 9 Su (10.1016/j.jmii.2021.08.012_bib37) 2019; 52 Ayukekbong (10.1016/j.jmii.2021.08.012_bib39) 2017; 6 Sheu (10.1016/j.jmii.2021.08.012_bib3) 2019; 10 Roope (10.1016/j.jmii.2021.08.012_bib24) 2019; 364 Kao (10.1016/j.jmii.2021.08.012_bib30) 2016; 16 Hsueh (10.1016/j.jmii.2021.08.012_bib13) 2019; 74 Lin (10.1016/j.jmii.2021.08.012_bib40) 2020; 53 Bhavnani (10.1016/j.jmii.2021.08.012_bib26) 2020; 7 Kallberg (10.1016/j.jmii.2021.08.012_bib15) 2018; 13 Martinez (10.1016/j.jmii.2021.08.012_bib25) 2011; 11 Suzuki (10.1016/j.jmii.2021.08.012_bib1) 2021; 76 Koizumi (10.1016/j.jmii.2021.08.012_bib41) 2019; 52 Tacconelli (10.1016/j.jmii.2021.08.012_bib17) 2018; 18 Zheng (10.1016/j.jmii.2021.08.012_bib23) 2020; 53 Liu (10.1016/j.jmii.2021.08.012_bib2) 2019; 52 Feng (10.1016/j.jmii.2021.08.012_bib5) 2021; 52 Baltas (10.1016/j.jmii.2021.08.012_bib11) 2021; 76 Liu (10.1016/j.jmii.2021.08.012_bib10) 2016; 49 Yang (10.1016/j.jmii.2021.08.012_bib31) 2020; 65 Chusri (10.1016/j.jmii.2021.08.012_bib7) 2019; 52 Bartsch (10.1016/j.jmii.2021.08.012_bib38) 2016; 54 Jackson (10.1016/j.jmii.2021.08.012_bib12) 2018; 73 Walters (10.1016/j.jmii.2021.08.012_bib8) 2019; 25 Livermore (10.1016/j.jmii.2021.08.012_bib29) 2017; 72 Liu (10.1016/j.jmii.2021.08.012_bib6) 2015; 5 Morrissey (10.1016/j.jmii.2021.08.012_bib20) 2019; 63 Humphries (10.1016/j.jmii.2021.08.012_bib16) 2016; 63 Gallagher (10.1016/j.jmii.2021.08.012_bib35) 2019; 69 Liu (10.1016/j.jmii.2021.08.012_bib21) 2019; 52 Du (10.1016/j.jmii.2021.08.012_bib9) 2019; 47 Jean (10.1016/j.jmii.2021.08.012_bib28) 2019; 17 Liao (10.1016/j.jmii.2021.08.012_bib14) 2019; 12 Felmingham (10.1016/j.jmii.2021.08.012_bib18) 2002; 50 Parsels (10.1016/j.jmii.2021.08.012_bib27) 2021; 76 Morrissey (10.1016/j.jmii.2021.08.012_bib34) 2020; 64 |
| References_xml | – volume: 61 year: 2017 ident: bib33 article-title: Surveillance of omadacycline activity against clinical isolates from a global collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011 publication-title: Antimicrob Agents Chemother – volume: 5 start-page: 11715 year: 2015 ident: bib6 article-title: Influence of carbapenem resistance on mortality of patients with publication-title: Sci Rep – volume: 73 start-page: 1452 year: 2018 end-page: 1459 ident: bib12 article-title: Discovery and development of new antibacterial drugs: learning from experience? publication-title: J Antimicrob Chemother – volume: 12 start-page: 545 year: 2019 end-page: 552 ident: bib14 article-title: Antimicrobial activities of ceftazidime-avibactam, ceftolozane-tazobactam, and other agents against publication-title: Infect Drug Resist – volume: 10 start-page: 80 year: 2019 ident: bib3 article-title: Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options publication-title: Front Microbiol – volume: 6 start-page: 47 year: 2017 ident: bib39 article-title: The threat of antimicrobial resistance in developing countries: causes and control strategies publication-title: Antimicrob Resist Infect Contr – volume: 13 year: 2018 ident: bib15 article-title: Introduction and geographic availability of new antibiotics approved between 1999 and 2014 publication-title: PloS One – volume: 52 start-page: 796 year: 2019 end-page: 806 ident: bib7 article-title: Clinical characteristics and outcomes of community and hospital-acquired publication-title: J Microbiol Immunol Infect – volume: 11 start-page: 439 year: 2011 end-page: 445 ident: bib25 article-title: Beyond serial passages: new methods for predicting the emergence of resistance to novel antibiotics publication-title: Curr Opin Pharmacol – volume: 16 start-page: 107 year: 2016 ident: bib30 article-title: Overproduction of active efflux pump and variations of OprD dominate in imipenem-resistant publication-title: BMC Microbiol – volume: 47 start-page: 1140 year: 2019 end-page: 1145 ident: bib9 article-title: Predictors of mortality in patients infected with carbapenem-resistant publication-title: Am J Infect Contr – volume: 364 year: 2019 ident: bib24 article-title: The challenge of antimicrobial resistance: what economics can contribute publication-title: Science – volume: 52 start-page: 956 year: 2019 end-page: 965 ident: bib21 article-title: A multicenter study on clinical characteristics of publication-title: J Microbiol Immunol Infect – volume: 72 start-page: 2278 year: 2017 end-page: 2289 ident: bib29 article-title: Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, publication-title: J Antimicrob Chemother – volume: 52 start-page: 261 year: 2021 end-page: 266 ident: bib5 article-title: Changes in the resistance and epidemiological characteristics of publication-title: J Microbiol Immunol Infect – volume: 53 start-page: 647 year: 2020 end-page: 651 ident: bib22 article-title: An unusual community-acquired invasive and multi systemic infection due to ExoU-harboring publication-title: J Microbiol Immunol Infect – volume: 69 start-page: S1 year: 2019 end-page: S5 ident: bib35 article-title: Omadacycline: a modernized tetracycline publication-title: Clin Infect Dis – volume: 76 start-page: 1379 year: 2021 end-page: 1391 ident: bib27 article-title: Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections publication-title: J Antimicrob Chemother – volume: 52 start-page: 365 year: 2019 end-page: 366 ident: bib37 article-title: Severe community-acquired pneumonia due to publication-title: J Microbiol Immunol Infect – volume: 63 start-page: 83 year: 2016 end-page: 88 ident: bib16 article-title: Emerging resistance, new antimicrobial agents but no tests! the challenge of antimicrobial susceptibility testing in the current US regulatory landscape publication-title: Clin Infect Dis – volume: 65 year: 2020 ident: bib31 article-title: In vitro activity of cefepime-zidebactam, ceftazidime-avibactam, and other comparators against clinical isolates of Enterobacterales, publication-title: Antimicrob Agents Chemother – volume: 49 start-page: 934 year: 2016 end-page: 940 ident: bib10 article-title: Risk factors of mortality in patients with carbapenem-resistant publication-title: J Microbiol Immunol Infect – year: 2021 ident: bib19 article-title: Performance standards for antimicrobial susceptibility testing: 30th informational supplement M100-ED31 – volume: 9 start-page: 275 year: 2020 ident: bib4 article-title: Epidemiology, treatment, and prevention of nosocomial bacterial pneumonia publication-title: J Clin Med – volume: 25 start-page: 1281 year: 2019 end-page: 1288 ident: bib8 article-title: Carbapenem-resistant publication-title: Emerg Infect Dis – volume: 64 year: 2020 ident: bib34 article-title: In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017 publication-title: Antimicrob Agents Chemother – volume: 4 start-page: S366 year: 2017 end-page: S367 ident: bib32 article-title: Activity of the novel extended-spectrum β-Lactamase inhibitor AAI101 in combination with cefepime towards a challenge panel of publication-title: Open Forum Infect Dis – volume: 50 start-page: 1 year: 2002 end-page: 7 ident: bib18 article-title: The need for antimicrobial resistance surveillance publication-title: J Antimicrob Chemother – volume: 7 start-page: ofaa083 year: 2020 ident: bib26 article-title: A broken antibiotic market: review of strategies to incentivize drug development publication-title: Open Forum Infect Dis – volume: 76 start-page: 1358 year: 2021 end-page: 1365 ident: bib1 article-title: A comprehensive assessment of carbapenem use across 90 Veterans Health Administration hospitals with defined stewardship strategies for carbapenems publication-title: J Antimicrob Chemother – volume: 54 start-page: 2757 year: 2016 end-page: 2762 ident: bib38 article-title: Impact of delays between clinical and laboratory Standards Institute and Food and drug administration revisions of interpretive criteria for carbapenem-resistant Enterobacteriaceae publication-title: J Clin Microbiol – volume: 52 start-page: 966 year: 2019 end-page: 972 ident: bib41 article-title: The clinical characteristics of publication-title: J Microbiol Immunol Infect – volume: 74 start-page: 380 year: 2019 end-page: 386 ident: bib13 article-title: In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant publication-title: J Antimicrob Chemother – volume: 30 start-page: 381 year: 2017 end-page: 407 ident: bib36 article-title: Antimicrobial stewardship: how the microbiology laboratory can right the ship publication-title: Clin Microbiol Rev – volume: 17 start-page: 307 year: 2019 end-page: 309 ident: bib28 article-title: Cefiderocol: a promising antibiotic against multidrug-resistant Gram-negative bacteria publication-title: Expert Rev Anti Infect Ther – volume: 53 start-page: 1030 year: 2020 end-page: 1034 ident: bib40 article-title: sepsis presenting as oral ecthyma gangrenosum in identical twins with Bruton tyrosine kinase gene mutation: two case reports and review of the literature publication-title: J Microbiol Immunol Infect – volume: 63 start-page: e00514 year: 2019 end-page: e00519 ident: bib20 article-title: In vitro activity of cefepime-enmetazobactam against Gram-negative isolates collected from U.S. and European hospitals during 2014-2015 publication-title: Antimicrob Agents Chemother – volume: 53 start-page: 854 year: 2020 end-page: 865 ident: bib23 article-title: Colistin for pneumonia involving multidrug-resistant publication-title: J Microbiol Immunol Infect – volume: 52 start-page: 788 year: 2019 end-page: 795 ident: bib2 article-title: Comparative efficacy of doripenem versus meropenem for hospital-acquired and ventilator-associated pneumonia publication-title: J Microbiol Immunol Infect – volume: 18 start-page: 318 year: 2018 end-page: 327 ident: bib17 article-title: Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis publication-title: Lancet Infect Dis – volume: 76 start-page: 813 year: 2021 end-page: 819 ident: bib11 article-title: Impact of antibiotic timing on mortality from Gram-negative bacteraemia in an English district general hospital: the importance of getting it right every time publication-title: J Antimicrob Chemother – volume: 63 start-page: e00514 year: 2019 ident: 10.1016/j.jmii.2021.08.012_bib20 article-title: In vitro activity of cefepime-enmetazobactam against Gram-negative isolates collected from U.S. and European hospitals during 2014-2015 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00514-19 – volume: 49 start-page: 934 year: 2016 ident: 10.1016/j.jmii.2021.08.012_bib10 article-title: Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia publication-title: J Microbiol Immunol Infect doi: 10.1016/j.jmii.2014.10.006 – volume: 64 year: 2020 ident: 10.1016/j.jmii.2021.08.012_bib34 article-title: In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017 publication-title: Antimicrob Agents Chemother – volume: 52 start-page: 788 year: 2019 ident: 10.1016/j.jmii.2021.08.012_bib2 article-title: Comparative efficacy of doripenem versus meropenem for hospital-acquired and ventilator-associated pneumonia publication-title: J Microbiol Immunol Infect doi: 10.1016/j.jmii.2019.04.008 – volume: 63 start-page: 83 year: 2016 ident: 10.1016/j.jmii.2021.08.012_bib16 article-title: Emerging resistance, new antimicrobial agents but no tests! the challenge of antimicrobial susceptibility testing in the current US regulatory landscape publication-title: Clin Infect Dis doi: 10.1093/cid/ciw201 – volume: 52 start-page: 365 year: 2019 ident: 10.1016/j.jmii.2021.08.012_bib37 article-title: Severe community-acquired pneumonia due to Pseudomonas aeruginosa coinfection in an influenza A(H1N1)pdm09 patient publication-title: J Microbiol Immunol Infect doi: 10.1016/j.jmii.2018.05.007 – volume: 9 start-page: 275 year: 2020 ident: 10.1016/j.jmii.2021.08.012_bib4 article-title: Epidemiology, treatment, and prevention of nosocomial bacterial pneumonia publication-title: J Clin Med doi: 10.3390/jcm9010275 – volume: 25 start-page: 1281 year: 2019 ident: 10.1016/j.jmii.2021.08.012_bib8 article-title: Carbapenem-resistant Pseudomonas aeruginosa at US emerging infections program sites, 2015 publication-title: Emerg Infect Dis doi: 10.3201/eid2507.181200 – volume: 12 start-page: 545 year: 2019 ident: 10.1016/j.jmii.2021.08.012_bib14 publication-title: Infect Drug Resist doi: 10.2147/IDR.S193638 – volume: 7 start-page: ofaa083 year: 2020 ident: 10.1016/j.jmii.2021.08.012_bib26 article-title: A broken antibiotic market: review of strategies to incentivize drug development publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofaa083 – volume: 6 start-page: 47 year: 2017 ident: 10.1016/j.jmii.2021.08.012_bib39 article-title: The threat of antimicrobial resistance in developing countries: causes and control strategies publication-title: Antimicrob Resist Infect Contr doi: 10.1186/s13756-017-0208-x – volume: 76 start-page: 1358 year: 2021 ident: 10.1016/j.jmii.2021.08.012_bib1 article-title: A comprehensive assessment of carbapenem use across 90 Veterans Health Administration hospitals with defined stewardship strategies for carbapenems publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkab008 – volume: 52 start-page: 261 year: 2021 ident: 10.1016/j.jmii.2021.08.012_bib5 article-title: Changes in the resistance and epidemiological characteristics of Pseudomonas aeruginosa during a ten-year period publication-title: J Microbiol Immunol Infect doi: 10.1016/j.jmii.2019.08.017 – volume: 52 start-page: 796 year: 2019 ident: 10.1016/j.jmii.2021.08.012_bib7 article-title: Clinical characteristics and outcomes of community and hospital-acquired Acinetobacter baumannii bacteremia publication-title: J Microbiol Immunol Infect doi: 10.1016/j.jmii.2019.03.004 – volume: 50 start-page: 1 issue: Suppl S1 year: 2002 ident: 10.1016/j.jmii.2021.08.012_bib18 article-title: The need for antimicrobial resistance surveillance publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkf807 – volume: 69 start-page: S1 year: 2019 ident: 10.1016/j.jmii.2021.08.012_bib35 article-title: Omadacycline: a modernized tetracycline publication-title: Clin Infect Dis doi: 10.1093/cid/ciz394 – volume: 53 start-page: 1030 year: 2020 ident: 10.1016/j.jmii.2021.08.012_bib40 article-title: Pseudomonas aeruginosa sepsis presenting as oral ecthyma gangrenosum in identical twins with Bruton tyrosine kinase gene mutation: two case reports and review of the literature publication-title: J Microbiol Immunol Infect doi: 10.1016/j.jmii.2020.04.009 – volume: 16 start-page: 107 year: 2016 ident: 10.1016/j.jmii.2021.08.012_bib30 article-title: Overproduction of active efflux pump and variations of OprD dominate in imipenem-resistant Pseudomonas aeruginosa isolated from patients with bloodstream infections in Taiwan publication-title: BMC Microbiol doi: 10.1186/s12866-016-0719-2 – volume: 364 year: 2019 ident: 10.1016/j.jmii.2021.08.012_bib24 article-title: The challenge of antimicrobial resistance: what economics can contribute publication-title: Science doi: 10.1126/science.aau4679 – volume: 72 start-page: 2278 year: 2017 ident: 10.1016/j.jmii.2021.08.012_bib29 article-title: Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkx136 – volume: 65 year: 2020 ident: 10.1016/j.jmii.2021.08.012_bib31 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01726-20 – volume: 53 start-page: 854 year: 2020 ident: 10.1016/j.jmii.2021.08.012_bib23 article-title: Colistin for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex publication-title: J Microbiol Immunol Infect doi: 10.1016/j.jmii.2019.08.007 – volume: 54 start-page: 2757 year: 2016 ident: 10.1016/j.jmii.2021.08.012_bib38 article-title: Impact of delays between clinical and laboratory Standards Institute and Food and drug administration revisions of interpretive criteria for carbapenem-resistant Enterobacteriaceae publication-title: J Clin Microbiol doi: 10.1128/JCM.00635-16 – volume: 61 year: 2017 ident: 10.1016/j.jmii.2021.08.012_bib33 article-title: Surveillance of omadacycline activity against clinical isolates from a global collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00018-17 – volume: 74 start-page: 380 year: 2019 ident: 10.1016/j.jmii.2021.08.012_bib13 publication-title: J Antimicrob Chemother doi: 10.1093/jac/dky425 – volume: 52 start-page: 966 year: 2019 ident: 10.1016/j.jmii.2021.08.012_bib41 article-title: The clinical characteristics of Acinetobacter bacteremia differ among genomospecies: a hospital-based retrospective comparative analysis of genotypically identified strains publication-title: J Microbiol Immunol Infect doi: 10.1016/j.jmii.2019.09.007 – volume: 5 start-page: 11715 year: 2015 ident: 10.1016/j.jmii.2021.08.012_bib6 article-title: Influence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection: a meta-analysis publication-title: Sci Rep doi: 10.1038/srep11715 – volume: 76 start-page: 1379 year: 2021 ident: 10.1016/j.jmii.2021.08.012_bib27 article-title: Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkab015 – volume: 13 year: 2018 ident: 10.1016/j.jmii.2021.08.012_bib15 article-title: Introduction and geographic availability of new antibiotics approved between 1999 and 2014 publication-title: PloS One doi: 10.1371/journal.pone.0205166 – volume: 76 start-page: 813 year: 2021 ident: 10.1016/j.jmii.2021.08.012_bib11 article-title: Impact of antibiotic timing on mortality from Gram-negative bacteraemia in an English district general hospital: the importance of getting it right every time publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkaa478 – volume: 10 start-page: 80 year: 2019 ident: 10.1016/j.jmii.2021.08.012_bib3 article-title: Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options publication-title: Front Microbiol doi: 10.3389/fmicb.2019.00080 – volume: 47 start-page: 1140 year: 2019 ident: 10.1016/j.jmii.2021.08.012_bib9 article-title: Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis publication-title: Am J Infect Contr doi: 10.1016/j.ajic.2019.03.003 – volume: 18 start-page: 318 year: 2018 ident: 10.1016/j.jmii.2021.08.012_bib17 article-title: Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(17)30753-3 – volume: 4 start-page: S366 year: 2017 ident: 10.1016/j.jmii.2021.08.012_bib32 article-title: Activity of the novel extended-spectrum β-Lactamase inhibitor AAI101 in combination with cefepime towards a challenge panel of Acinetobacter baumannii publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofx163.896 – volume: 53 start-page: 647 year: 2020 ident: 10.1016/j.jmii.2021.08.012_bib22 article-title: An unusual community-acquired invasive and multi systemic infection due to ExoU-harboring Pseudomonas aeruginosa strain: clinical disease and microbiological characteristics publication-title: J Microbiol Immunol Infect doi: 10.1016/j.jmii.2019.06.008 – volume: 73 start-page: 1452 year: 2018 ident: 10.1016/j.jmii.2021.08.012_bib12 article-title: Discovery and development of new antibacterial drugs: learning from experience? publication-title: J Antimicrob Chemother doi: 10.1093/jac/dky019 – year: 2021 ident: 10.1016/j.jmii.2021.08.012_bib19 – volume: 11 start-page: 439 year: 2011 ident: 10.1016/j.jmii.2021.08.012_bib25 article-title: Beyond serial passages: new methods for predicting the emergence of resistance to novel antibiotics publication-title: Curr Opin Pharmacol doi: 10.1016/j.coph.2011.07.005 – volume: 17 start-page: 307 year: 2019 ident: 10.1016/j.jmii.2021.08.012_bib28 article-title: Cefiderocol: a promising antibiotic against multidrug-resistant Gram-negative bacteria publication-title: Expert Rev Anti Infect Ther doi: 10.1080/14787210.2019.1612240 – volume: 30 start-page: 381 year: 2017 ident: 10.1016/j.jmii.2021.08.012_bib36 article-title: Antimicrobial stewardship: how the microbiology laboratory can right the ship publication-title: Clin Microbiol Rev doi: 10.1128/CMR.00066-16 – volume: 52 start-page: 956 year: 2019 ident: 10.1016/j.jmii.2021.08.012_bib21 article-title: A multicenter study on clinical characteristics of Acinetobacter bacteremia in patients with liver cirrhosis publication-title: J Microbiol Immunol Infect doi: 10.1016/j.jmii.2018.03.001 |
| SSID | ssj0043256 |
| Score | 2.445209 |
| Snippet | This study aimed to investigate the in vitro susceptibilities of carbapenem-non-susceptible Pseudomonas aeruginosa (CNSPA) and Acinetobacter baumannii (CNSAB)... This study aimed to investigate the in vitro susceptibilities of carbapenem-non-susceptible Pseudomonas aeruginosa (CNSPA) and Acinetobacter baumannii (CNSAB)... Background/purpose: This study aimed to investigate the in vitro susceptibilities of carbapenem-non-susceptible Pseudomonas aeruginosa (CNSPA) and... |
| SourceID | doaj proquest pubmed crossref elsevier |
| SourceType | Open Website Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 888 |
| SubjectTerms | Acinetobacter baumannii Amikacin - pharmacology Anti-Bacterial Agents - pharmacology beta-Lactamase Inhibitors - pharmacology Carbapenems - pharmacology Cefepime - pharmacology Cefepime/enmetazobactam Cefepime/zidebactam Cefiderocol Ceftazidime - pharmacology Cephalosporins - pharmacology Drug Resistance, Multiple, Bacterial Eravacycline Humans Omadacycline Pseudomonas aeruginosa Sepsis Taiwan Tazobactam Tetracyclines - pharmacology Tigecycline - pharmacology |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwEDaoEhIXxD9bfmQkbmzUJHac7LEgqoIE4tBKvUX-GaNUTbLaZIvaE-_AC_AsPApPwoyTbNsD7YXTbrJjJ17PjD_L880w9iYpfC6KXEcLp1wkfSKihcl85BNjMmGUH5I9f_6i9g_lp6Ps6FKpL4oJG9IDD3_cjhPSCeEp0biUsYu1z2LjIXaZMS6RnrwvrnnTZmrwwVKkoW5rogoZEYQe6TJDZNdxXVW4M0yH5J1JemVJCpn7r6xM_0KeYQXau8_ujdCR7w6v_IDdhuYhuzMUkzx7dGv-sfn967TqVy0nsgLVhOCt5xY8Me1anPA5XcCyqmEHmhp6fY7GbHtdX_rhHIWnm7DSp9qeEXkS5ryttbu40o3jgbzF7UX-cK6JqNXhh64QdnJLhxlL9KZ11LRN1K27EERjToB_7WDtWrQBjeKwWn-rmrbTodtdOuvvw6th90bTMUNTVbxCMyFkzPWoUuA4sWN4CL4n0ouu-RRc1uA3fqCr77rhYywaRxRS_PnxE-ckfswO9z4cvN-PxloQkc2SvI-Uzjxkea6kt2pRxDj5CsFmaiCVpgAfo055ZYrU5lAoKwufWvQtILxZOJk68YRt4UjhGeOAkFMrA85ZjfBF6NxmwgHKaqOkUjOWTOpQ2jFROtXrOCmniLjjklSoJBUqqYhnks7Y202b5ZAm5Frpd6RlG0lK8R1uoOKXo-KXNyn-jIlJR8uJRYt-Hzuqrn10tmk1YqwBO93Y7vVkBiU6IDpV0g20665En5_iJh79_ow9HexjMzAhER1mi2T7fwz4ObubEvckRFK-YFv9ag0vERH25lUw_r8HlmcI priority: 102 providerName: Directory of Open Access Journals |
| Title | In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018–2020 |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1684118221001869 https://dx.doi.org/10.1016/j.jmii.2021.08.012 https://www.ncbi.nlm.nih.gov/pubmed/34521591 https://www.proquest.com/docview/2572924870 https://doaj.org/article/d34d33f2182440d0af50bfe0d5bbd14f |
| Volume | 55 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwEDZVJSQuiH-Wn8pI3NiwSew42WOpqAoSCIlW6i3yb-WqSVabbFF7QLwDL8Cz8Cg8CTNOsmUPFInTbrxjJ97MjL_E880Q8jIpXM6KXEZzI0zEXcKiucpc5BKlMqaE65M9f_goDo74--PseIvsjVwYDKscfH_v04O3Hlpmw785W3g_-5yIgiM8TjGNUCGQxMd5jlr--us6zIOzNFRwReEIpQfiTB_jdVp5D8-IaZ_GM0k3FqeQw39jjfobBg1r0f4dcnsAkXS3v867ZMvW98jNvqzkxf0b03f1zx_nvls2FGkLWB2CNo5q65Bz18Ctn-KBXfjKzmxd2U5eglnrTlZ__HAJwmOjXcpzqS-QRmmntKmkuTqStaGBxkX1VSZxKpGy1cKH9ABAqcZtjQX41SqqmzpqV20Ip1Fnln5q7co0YA0SxO1ydeLrppVh2F3c9e_CpcHwSuKGQ-099WAwiJGpHJTLGoo8GRrC8JH-Iis6hpnV8I0eSv9F1nSISqOAR4pf377DPYkfkKP9t4d7B9FQFSLSWZJ3kZCZs1meC-60mBexUkYA7EyVTbkqrItBu5xQRapzWwjNC5dq8DKWOTU3PDXsIdmGmdrHhFoAn1Ioa4yWAGSYzHXGjAVZqQQXYkKSUR1KPaRMx8odZ-UYG3daogqVqEIllvNM0gl5te6z6BOGXCv9BrVsLYnJvkNDszwpB20vDeOGMYe59jmPTSxdFitnY5PB3BPuJoSNOlqOfFpYAWAgf-2ps3WvDYv7Z78XoxmU4Ipwf0nWtlm1JXj_FB7nYQWYkEe9fawnxjjgxGyePPnPsz4lt1IknoQwymdku1uu7HOAg53aCfa-E16m_Ab6-Gev |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwEDalCMEF8c_yayRuNN0kdpzssVRUW2grJLZSb5F_K1dNstrNFrUHxDvwAjwLj8KTMJOfLXugSJyy8Y6dOJkZf5HnmyHkTZS5lGWpDEZGmIC7iAUjlbjARUolTAnXJnvePxDjQ_7hKDlaI9s9FwbDKjvf3_r0xlt3LcPuaQ6n3g8_RyLjCI9jTCOUidF1coOD-aJ1bn5dxnlwFjclXFE6QPGOOdMGeZ0U3sNHYtzm8YzildWpSeK_skj9DYQ2i9HOXXKnQ5F0q73Re2TNlvfJzbau5PmDaxu75c8fZ76eVRR5C1geglaOauuQdFfBu9_AEzv1hR3asrC1vAC71rUs_vjjAoT7RjuTZ1KfI4_SbtCqkObyTJaGNjwuqi9TiVOJnK05HKQHBEo17mtMwbEWQVmVwXwxb-Jp1Kmln-Z2YSowBwnidrY49mU1l82wW7jtXze3BsMriTsOpffUg8UgSKay0y5rKBJlaBOHj_wXWdA-zqyEX3Qi_RdZ0i4sjQIgyX59-w7vJHxIDnfeT7bHQVcWItBJlNaBkImzSZoK7rQYZaFSRgDujJWNucqsC0G9nFBZrFObCc0zF2twM5Y5NTI8NuwRWYeZ2ieEWkCfUihrjJaAZJhMdcKMBVmpBBdiQKJeHXLd5UzH0h2neR8cd5KjCuWoQjnW84ziAXm77DNtM4ZcKf0OtWwpidm-m4Zqdpx36p4bxg1jDpPtcx6aULokVM6GJoG5R9wNCOt1NO8JtbAEwED-yksny14rJvfPfq97M8jBF-EGkyxttZjn4P5j-J6HJWBAHrf2sZwY4wAUk1H09D-v-orcGk_29_K93YOPz8jtGFkoTUzlc7Jezxb2BWDDWr1sbP83ayJp1Q |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=In%C2%A0vitro+activity+of+cefiderocol%2C+cefepime%2Fenmetazobactam%2C+cefepime%2Fzidebactam%2C+eravacycline%2C+omadacycline%2C+and+other+comparative+agents+against+carbapenem-non-susceptible+Pseudomonas+aeruginosa+and+Acinetobacter+baumannii+isolates+associated+from+bloodstream+infection+in+Taiwan+between+2018%E2%80%932020&rft.jtitle=Journal+of+microbiology%2C+immunology+and+infection&rft.au=Liu%2C+Po-Yu&rft.au=Ko%2C+Wen-Chien&rft.au=Lee%2C+Wen-Sen&rft.au=Lu%2C+Po-Liang&rft.date=2022-10-01&rft.issn=1684-1182&rft.volume=55&rft.issue=5&rft.spage=888&rft.epage=895&rft_id=info:doi/10.1016%2Fj.jmii.2021.08.012&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_jmii_2021_08_012 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1684-1182&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1684-1182&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1684-1182&client=summon |